Pancreas Volume and Diabetes Status Following Pancreatectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will enroll 100 patients scheduled to undergo a pancreatectomy.

The primary objective is to develop a scoring system using pancreatic volume measured by CT scan and intraoperative measurements of the pancreas parenchyma to predict the onset of diabetes mellitus after a pancreatectomy. The investigators will also monitor patients with pre-existing diabetes to see if their diabetes worsens or improves.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adipose Tissue Function After Pancreas Transplantation

NCT01729130

Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 End Stage Renal Disease

COMPLETED

Hepatic Histology and Metabolism Following Total Pancreatectomy and Pancreaticoduodenectomy

NCT03864744

Total Pancreatectomy Pancreaticoduodenectomy Pancreatic Diabetes +3 more

UNKNOWN

Establishment and Verification of Pancreatic Volume Formula Based on Imaging

NCT05410795

Healthy People Chronic Pancreatitis Acute Pancreatitis

UNKNOWN

Incidence and Risk Factor of Post-ERCP Pancreatitis in Chronic Pancreatitis

NCT02781987

Post-ERCP Acute Pancreatitis

COMPLETED

The Impact of Hepatic Steatosis on Survival After Pancreaticoduodenectomy

NCT07182136

Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective is to develop a scoring system using pancreatic volume measured by CT scan and intraoperative measurements of the pancreas parenchyma to predict the onset of diabetes mellitus after a pancreatectomy. The investigators will also monitor patients with pre-existing diabetes to see if their diabetes worsens or improves. Patients will be followed up to one year to track their diabetes status, postoperative outcomes and quality of life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pancreatectomy

Patients scheduled to undergo a pancreatectomy

Pancreatectomy

Intervention Type PROCEDURE

Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pancreatectomy

Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients undergoing pancreatectomy at our institution (e.g., pancreaticoduodenectomy, distal pancreatectomy, distal pancreatectomy and splenectomy, central pancreatectomy).

Exclusion Criteria

* All patients who are on steroids or other medications whose potential side effects include development of diabetes mellitus or elevated blood glucose.
* Pregnant or nursing women.
* Patients with uncontrolled diabetes (HbA1c \>8%).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No